Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Yale University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00719875
First received: July 18, 2008
Last updated: June 5, 2009
Last verified: June 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2010
  Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)